| Dr Steven Earl Weinstein, DO | |
|
29 Palms Naval Hospital, Magtftc Mcagcc, Twenty Nine Palms, CA 92278-8250 | |
| (760) 830-2194 | |
| Not Available |
| Full Name | Dr Steven Earl Weinstein |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 26 Years |
| Location | 29 Palms Naval Hospital, Twenty Nine Palms, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962503805 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 20A7567 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Grossmont Hospital | La mesa, CA | Hospital |
| Scripps Green Hospital | La jolla, CA | Hospital |
| Kaiser Foundation Hospital - Antioch | Antioch, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Team Physicians Of Northern California Medical Group Inc | 7113215146 | 95 |
| Scripps Health | 9234033853 | 1362 |
News Archive
Porvair Sciences has developed a new ChIP sequencing assay kit extending the benefits of their proprietary Chromatrap® solid state ChIP technology to preparation of purified Chromatin for the generation of sequencing libraries.
For patients undergoing surgery to repair a bunion deformity of the foot, non-weight-bearing x rays taken immediately after surgery can provide a good estimate of the risk that the bunion will return over time, reports a study in the current issue of The Journal of Bone & Joint Surgery.
Repros Therapeutics Inc. today announced it has received IRB approval to commence the low dose Proellex® study. The contract for clinical services was previously awarded to ICON. The new low dose study is designed to explore both safety and signals of efficacy in an escalating dose fashion. The study will test 5 different doses of Proellex (1, 3, 6, 9 and 12 mg) with 1 mg being the first dose tested. In previous studies a 12.5 mg dose was well tolerated and yielded statistically significant efficacy signals for both uterine fibroids and endometriosis.
Adherence to the oral anticoagulant apixaban among patients with atrial fibrillation (AF) was no better for those who received an educational program compared to those who did not, results of the international, randomised AEGEAN trial show.
Acorda Therapeutics, Inc. today announced that it has acquired two neuropathic pain management assets from NeurogesX, Inc. Qutenza is approved by the U.S. Food and Drug Administration for the management of neuropathic pain associated with postherpetic neuralgia.
› Verified 9 days ago
| Entity Name | Scripps Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881636108 PECOS PAC ID: 9234033853 Enrollment ID: O20031124000822 |
News Archive
Porvair Sciences has developed a new ChIP sequencing assay kit extending the benefits of their proprietary Chromatrap® solid state ChIP technology to preparation of purified Chromatin for the generation of sequencing libraries.
For patients undergoing surgery to repair a bunion deformity of the foot, non-weight-bearing x rays taken immediately after surgery can provide a good estimate of the risk that the bunion will return over time, reports a study in the current issue of The Journal of Bone & Joint Surgery.
Repros Therapeutics Inc. today announced it has received IRB approval to commence the low dose Proellex® study. The contract for clinical services was previously awarded to ICON. The new low dose study is designed to explore both safety and signals of efficacy in an escalating dose fashion. The study will test 5 different doses of Proellex (1, 3, 6, 9 and 12 mg) with 1 mg being the first dose tested. In previous studies a 12.5 mg dose was well tolerated and yielded statistically significant efficacy signals for both uterine fibroids and endometriosis.
Adherence to the oral anticoagulant apixaban among patients with atrial fibrillation (AF) was no better for those who received an educational program compared to those who did not, results of the international, randomised AEGEAN trial show.
Acorda Therapeutics, Inc. today announced that it has acquired two neuropathic pain management assets from NeurogesX, Inc. Qutenza is approved by the U.S. Food and Drug Administration for the management of neuropathic pain associated with postherpetic neuralgia.
› Verified 9 days ago
| Entity Name | Team Physicians Of Northern California Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649692716 PECOS PAC ID: 7113215146 Enrollment ID: O20161006002407 |
News Archive
Porvair Sciences has developed a new ChIP sequencing assay kit extending the benefits of their proprietary Chromatrap® solid state ChIP technology to preparation of purified Chromatin for the generation of sequencing libraries.
For patients undergoing surgery to repair a bunion deformity of the foot, non-weight-bearing x rays taken immediately after surgery can provide a good estimate of the risk that the bunion will return over time, reports a study in the current issue of The Journal of Bone & Joint Surgery.
Repros Therapeutics Inc. today announced it has received IRB approval to commence the low dose Proellex® study. The contract for clinical services was previously awarded to ICON. The new low dose study is designed to explore both safety and signals of efficacy in an escalating dose fashion. The study will test 5 different doses of Proellex (1, 3, 6, 9 and 12 mg) with 1 mg being the first dose tested. In previous studies a 12.5 mg dose was well tolerated and yielded statistically significant efficacy signals for both uterine fibroids and endometriosis.
Adherence to the oral anticoagulant apixaban among patients with atrial fibrillation (AF) was no better for those who received an educational program compared to those who did not, results of the international, randomised AEGEAN trial show.
Acorda Therapeutics, Inc. today announced that it has acquired two neuropathic pain management assets from NeurogesX, Inc. Qutenza is approved by the U.S. Food and Drug Administration for the management of neuropathic pain associated with postherpetic neuralgia.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Steven Earl Weinstein, DO 7369 Arroyo Grande Rd, San Diego, CA 92129-2261 Ph: (858) 945-1282 | Dr Steven Earl Weinstein, DO 29 Palms Naval Hospital, Magtftc Mcagcc, Twenty Nine Palms, CA 92278-8250 Ph: (760) 830-2194 |
News Archive
Porvair Sciences has developed a new ChIP sequencing assay kit extending the benefits of their proprietary Chromatrap® solid state ChIP technology to preparation of purified Chromatin for the generation of sequencing libraries.
For patients undergoing surgery to repair a bunion deformity of the foot, non-weight-bearing x rays taken immediately after surgery can provide a good estimate of the risk that the bunion will return over time, reports a study in the current issue of The Journal of Bone & Joint Surgery.
Repros Therapeutics Inc. today announced it has received IRB approval to commence the low dose Proellex® study. The contract for clinical services was previously awarded to ICON. The new low dose study is designed to explore both safety and signals of efficacy in an escalating dose fashion. The study will test 5 different doses of Proellex (1, 3, 6, 9 and 12 mg) with 1 mg being the first dose tested. In previous studies a 12.5 mg dose was well tolerated and yielded statistically significant efficacy signals for both uterine fibroids and endometriosis.
Adherence to the oral anticoagulant apixaban among patients with atrial fibrillation (AF) was no better for those who received an educational program compared to those who did not, results of the international, randomised AEGEAN trial show.
Acorda Therapeutics, Inc. today announced that it has acquired two neuropathic pain management assets from NeurogesX, Inc. Qutenza is approved by the U.S. Food and Drug Administration for the management of neuropathic pain associated with postherpetic neuralgia.
› Verified 9 days ago